Mesalazine (Mesalamine)

Category
Inflammatory Bowel Disease
Product code
89-57-6

Mesalazine (also known as Mesalamine) is an anti-inflammatory active pharmaceutical ingredient widely used for the treatment of inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. By inhibiting the production of pro-inflammatory mediators in the intestinal mucosa, Mesalazine helps reduce inflammation, control symptoms, and maintain remission. Its local action in the gastrointestinal tract provides targeted therapy with minimal systemic absorption. Pharmaceutical companies formulate Mesalazine into oral tablets, delayed-release capsules, and rectal suspensions or enemas, offering versatile options for localized and systemic treatment.

Common Mesalazine Uses and Treated Conditions

  • Ulcerative Colitis – Reduces inflammation and promotes remission in mild to moderate disease.
  • Crohn’s Disease (Colonic Involvement) – Helps manage localized inflammatory activity in the colon.
  • Maintenance Therapy – Supports long-term remission and reduces flare-ups in chronic inflammatory bowel disease.
  • Symptom Control – Alleviates diarrhea, rectal bleeding, and abdominal pain associated with inflammation.

Why Choose Cambrex as Your Generic API Manufacturer?

As a leading generic API supplier, Cambrex manufactures Mesalazine API in cGMP-compliant facilities, ensuring every batch meets stringent global quality and regulatory standards. Our technical expertise, robust quality systems, and proven regulatory track record empower clients to accelerate development timelines and achieve successful market approvals. We prioritize transparency, reliability, and scientific rigor at every stage of the supply chain making us your trusted generic API manufacturer.

For detailed chemical information on Mesalazine, visit the official CAS website.

If you’d like more information or to request a sample, contact our Generic API team today.

Mesalazine (Mesalamine)

Cambrex your API partner

Cambrex are a leading global supplier of generic APIs. From our sites in Italy, Sweden, and the USA, we work with generic drug companies well in advance of drug patent expiration, using high quality, non-patent-infringing processes to manufacture APIs.

Contact us